## **Trends in Parasitology** | Parasite of the Month

# Trypanosoma evansi

### Alireza Sazmand 💿, <sup>1,2,\*</sup> Marc Desquesnes 💿, <sup>3,4,5</sup> and Domenico Otranto 💿 <sup>1,6</sup>


<sup>1</sup>Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, 6517658978, Hamedan, Iran

<sup>2</sup>Zoonotic Diseases Research Center, Department of Food Hygiene and Safety, School of Public Health, Shahid Sadoughi University of Medical Sciences, 8915173160 Yazd, Iran <sup>3</sup>CIRAD, UMR InterTryp, F-34398 Montpellier, France


<sup>4</sup>InterTryp, Univ Montpellier, CIRAD, IRD, Montpellier, France

<sup>5</sup>ENVT, 23 Chemin des Capelles, 31076 Toulouse, France

<sup>6</sup>Department of Veterinary Medicine, University of Bari, Valenzano, 70010, Bari, Italy



Trypanosoma evansi, the causative agent of 'surra', is a flagellated hemoprotozoan parasite. It kills thousands of animals every year and causes significant animal morbidity and loss of productivity. T. evansi originated from Trypanosoma brucei through deletion of the maxicircle kinetoplast DNA which conferred the capacity for mechanical transmission by flies and allowed T. evansi to expand beyond the tsetse belt. Presently, it is the most widely distributed pathogenic trypanosome in Africa, Asia, and Latin America, but its potential for geographical extension is not limited, as shown by recent sporadic cases in Spain and France. The most susceptible animals are horses, dogs, camels, and buffaloes, but other domestic livestock and wild mammals (including Australian marsupials, experimentally) can also be infected. Test-and-treatment of infected hosts and mass treatment programs are recommended in high-prevalence settings. International trading of potential carriers is a risk.



Trends in Parasitology, June 2022, Vol. 38, No. 6 © 2022 Elsevier Ltd. All rights reserved.

### **KEY FACTS:**

T. evansi can affect all mammals and has a wide range of domestic and wild reservoirs.

Diagnosis is made by detection of parasites in blood. This method has low sensitivity when the parasites are few in number (e.g., in reservoirs and wild mammals) or absent in blood while present in the nervous system; surveillance is consequently challenging.

No vaccine is available because of the rapid changes in trypanosomal surface glycoproteins, supporting avoidance of immune responses.

Very rare human cases have been described from India, Vietnam, Sri Lanka, and Egypt. Clinical presentation among humans is quite similar to the first stage of the chronic form of human sleeping sickness caused by T. brucei.

### DISEASE FACTS:

Surra is a trypanosomal disease that affects multiple mammalian taxa, with variable clinical presentation, severity, and outcome.

Clinical presentation may include fever, anemia, edema, loss of weight and condition, overt emaciation, sometimes paralysis, and death.

Surra can occur as acute, subacute, or chronic disease, or it may be asymptomatic.

Treatment with melarsomine and quinapyramine is efficacious if applied early. Otherwise, surra is invariably fatal in highly susceptible individuals.

Better knowledge of distribution and treatment is needed.

\*Correspondence: alireza.sazmand@basu.ac.ir (A. Sazmand).



CellPress

### **Trends in Parasitology | Parasite of the Month**

### Acknowledgments

We thank Dr Dennis Lawler for proofreading the manuscript, and Dr Jairo Alfonso Mendoza-Roldan for assistance in the design of the first figure.

### **Declaration of interests**

The authors declare no competing interests.

#### Resources

www.oie.int/fileadmin/home/eng/health\_standards/tahm/3.01.21\_trypano\_surra.pdf https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4892

### Literature

- 1. Desquesnes, M. et al. (2013) Trypanosoma evansi and surra: a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspects. *Biomed. Res. Int.* 2013, 321237
- Desquesnes, M. et al. (2013) Trypanosoma evansi and surra: a review and perspectives on origin, history, distribution, taxonomy, morphology, hosts, and pathogenic effects. Biomed. Res. Int. 2013, 194176
- Aregawi, W.G. et al. (2019) Systematic review and meta-analysis on the global distribution, host range, and prevalence of Trypanosoma evansi. Parasit. Vectors 12, 67
- 4. Van Vinh Chau, N. *et al.* (2016) A clinical and epidemiological investigation of the first reported human infection with the zoonotic parasite *Trypanosoma evansi* in Southeast Asia. *Clin. Infect. Dis.* 62, 1002–1008
- 5. Truc, P. et al. (2013) Atypical human infections by animal trypanosomes. PLoS Negl. Trop. Dis. 7, e2256
- 6. Sazmand, A. et al. (2019) Zoonotic parasites of dromedary camels: so important, so ignored. Parasit. Vectors 12, 610
- 7. Bahari, A. *et al.* (2021) Molecular detection of zoonotic pathogens in the blood and tissues of camels (*Camelus dromedarius*) in central desert of Iran. Yale J. Biol. Med. 94, 249–258
- 8. Gutierrez, C. et al. (2010) Trypanosoma evansi: recent outbreaks in Europe. Vet. Parasitol. 174, 26–29
- Nguyen, V.-L. et al. (2021) Molecular detection of *Trypanosoma evansi* in dogs from India and Southeast Asia. Acta Trop. 220, 105935
- 10. Reid, S.A. (2002) Trypanosoma evansi control and containment in Australasia. Trends Parasitol. 18, 219–224

### TAXONOMY AND CLASSIFICATION:

PHYLUM: Euglenozoa CLASS: Kinetoplastea ORDER: Trypanosomatida FAMILY: Trypanosomatidae GENUS: *Trypanosoma* SPECIES: *T. evansi* 

